[2] Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases | https://t.co/ZN0l4j3voC #healtheconomics [3/4]
RT @Ted_LQ4L: Genetic Testing does more than assess #medicine compatibility. It also is used for #heartdisease diagnosis. This review finds…
Genetic Testing does more than assess #medicine compatibility. It also is used for #heartdisease diagnosis. This review finds overwhelming evidence of the cost-effectiveness of Pharmacogenomic prescribing for clopidogrel & warfarin. #Cardiology #Doctor
This review finds Pharmacogenomic guided prescribing yields overwhelming evidence of cost-effectiveness for CVD management, & holds enormous potential for reducing the chances of drug-related adverse events. https://t.co/Ubla7Et84v #cardiology #Doctor
RT @GIMJournal: The jury is still out on cost-effectiveness of #pharmacogenomics in guiding cardiovascular disease therapy #HeartHealth htt…
RT @emedgene: Is pharmacogenomics testing a cost-effective approach in CVD care? This systematic review finds PGx testing to be more afford…
Is pharmacogenomics testing a cost-effective approach in CVD care? This systematic review finds PGx testing to be more affordable, however affirms that cost-effectiveness varies across drugs and conditions.@GIMJournal https://t.co/iv7xhjCL4O
RT @GIMJournal: The jury is still out on cost-effectiveness of #pharmacogenomics in guiding cardiovascular disease therapy #HeartHealth htt…
RT @GIMJournal: The jury is still out on cost-effectiveness of #pharmacogenomics in guiding cardiovascular disease therapy #HeartHealth htt…
RT @GIMJournal: The jury is still out on cost-effectiveness of #pharmacogenomics in guiding cardiovascular disease therapy #HeartHealth htt…
The jury is still out on cost-effectiveness of #pharmacogenomics in guiding cardiovascular disease therapy #HeartHealth https://t.co/Q2MPLsSUrU #openaccess https://t.co/e5kcJDBehY
RT @jsantoyo: Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.…
Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases. https://t.co/ZueBpGiVN5
Authors conclusions: Supportive evidence exists for #clopidogrel– CYP2C19 and #warfarin–CYP2C9/VKORC1 for #pharmacogenomics (PGx) in cardiovascular disease (CVD) care. What we are waiting for? it is something to put into practice now, isn't it? https://t
RT @MuinJKhoury: This @GIMJournal systematic review finds mixed evidence on the cost-effectiveness of pharmacogenomics-guided treatment for…
RT @MuinJKhoury: This @GIMJournal systematic review finds mixed evidence on the cost-effectiveness of pharmacogenomics-guided treatment for…
RT @MuinJKhoury: This @GIMJournal systematic review finds mixed evidence on the cost-effectiveness of pharmacogenomics-guided treatment for…
This @GIMJournal systematic review finds mixed evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases. https://t.co/Gp8nmbRDHv https://t.co/R9ExUAYfdD